Empiric/pre-emptive anti-Candida therapy in non-neutropenic ICU patients.
Timsit JF, Chemam S, Bailly S.
F1000Prime Rep. 2015 Feb 3;7:21. doi: 10.12703/P7-21. eCollection 2015.
ABSTRACT: The potential of the systemic antifungal treatment of non-immunocompromised patients with sepsis, extra-digestive Candida colonization and multiple organ failure is unknown, although it represents three out of four antifungal treatments prescribed in intensive care units. It may allow an early treatment of invasive fungal infection at incubation phase, but exposes patients to unnecessary antifungal treatments with subsequent costs and antifungal selection pressure. As early diagnostic tests for invasive candidiasis are still considered insufficient, the potential of this strategy needs to be demonstrated by a randomized controlled trial. Such a trial is currently ongoing.
TRIAL REGISTRATION: ClinicalTrials.gov.